According to the findings of the NEPHSTROM clinical study, researchers have observed positive results from a unique cell treatment experiment for adults with diabetes. In November, the findings of the study were presented at the American Society of Nephrology’s Kidney Week, held in Orlando, Florida.

The study showed that a single dose of ORBCEL-M, given intravenously to carefully selected adults with worsening kidney disease due to diabetes, was safe and associated with better preservation of kidney function compared to a placebo. Patients taking part in the trial were followed closely for 18 months after receiving ORBCEL-M.

ORBCEL-M cell therapy is a mesenchymal stromal cell (MSC) preparation manufactured from healthy bone marrow that was discovered and developed in Galway by Orbsen Therapeutics Ltd. The trial was led by researchers from the Mario Negri Institute for Pharmacological Research IRCCS in Bergamo, Italy, in collaboration with medical centers in Galway, Bergamo, Birmingham, and Belfast.

The trial investigator stated that more than 40% of diabetic patients have evidence of kidney disease, referred to as "diabetic kidney disease" or DKD for short. He pointed out that such people are at high risk of requiring dialysis or kidney transplantation in the later stages.

Therefore, the goal of the further trial is to determine whether ORBCEL-M is safe and if it can slow the course of DKD to reduce the possibility of dialysis or transplantation. 

(Source: https://theprint.in/health/researchers-reveal-cell-therapy-may-reduce-kidney-damage-from-type-2-diabetes/1282194/ )